Novo Nordisk's competitive position is strengthening, driven by strong sales growth in Wegovy, Ozempic, and rare diseases. See why NVO stock is a Buy.

Novo Nordisk said Wednesday that it will work with the biotech Septerna to develop oral GLP-1 obesity drugs, as it races to catch up to competitor Eli Lilly’s efforts to bring a more convenient ...

The bundle will offer Novo Nordisk’s popular weight-loss drug at all its dosage strengths paired with a Hims & Hers membership providing "access to 24/7 care, ongoing clinical support, and ...

Novo Nordisk is doubling down on Valo, committing up to $190 million in the near term—and billions in the back end—to apply AI to up to 20 programs.

Ozempic and Wegovy maker Novo Nordisk ousted CEO Lars Fruergaard Jorgensen on Friday over concerns the company is losing its first-mover advantage in the highly competitive obesity drug market.

Novo Nordisk ’s big bet to improve on the success of its weight-loss drug franchise hit a stumbling block Friday, wiping out nearly $100 billion of the drugmaker’s stock-market value.

People using weight loss drugs like Ozempic and Wegovy drink less 00:19. Novo Nordisk, the maker of blockbuster weight loss drug Wegovy, said Friday its CEO was stepping down by "mutual agreement ...

The Danish drugmaker, which makes Ozempic and Wegovy, has seen its stock tumble as competition in the weight-loss drug market has grown fiercer. By Rebecca Robbins Novo Nordisk will replace its ...